52W 4.69 - 52 Market Cap (intraday) 93.43 M Total Cash (mrq) 107.67M SAN DIEGO, Sept. 15, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 2,250,000 shares of its common stock at a price to the public of $45.00 per share. The gross proceeds from this offering are expected to be approximately $101.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. Total Cash Per Share (mrq) 5.41 Total Debt (mrq) 0
Time for a stong recovery 2016/07/19 5.34 2016/07/13 5.65 2016/07/11 5.87 2016/06/17 7.19 2016/06/10 9.41 2016/06/03 19.2523 2015/09/15 52.00
Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of products targeting oncology. The company?s clinical stage product candidates include MGCD265, a multi-targeted kinase inhibitor that is in Phase 1b clinical development trials for the treatment of patients with non-small cell lung cancer and other solid tumors, such as those found in gastroesophageal cancers, and squamous cell carcinoma of the head and neck; and MGCD516, a kinase inhibitor, which is in Phase Ib clinical development for the treatment of solid tumors with an emphasis on genetic alterations. It also develops Mocetinostat, an orally-bioavailable histone deacetylase inhibitor that is in Phase 2 clinical trial development for patients with bladder cancer, myelodysplastic syndrome, and non-hodgkin's lymphoma, principally diffuse large B-cell lymphoma and follicular lymphoma. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for MGCD265; and a partnership with QIAGEN N.V. to develop and commercialize a companion diagnostic test to guide the use of glesatinib (MGCD265), a targeted therapy under development for non-small cell lung cancer. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.